Abbreviations: AACE = American Association of Clinical Endocrinologists; ACE = American College of Endocrinology; AME = Associazione Medici Endocrinologi; BEL = best evidence level; CNB = core-needle biopsy; CT = computed tomography; FNA = fine-needle aspiration; FT 3 = free triiodothyronine; FT 4 = free thyroxine; LT 4 = levothyroxine; MeSH = Medical Subject Headings; MNG = multinodular goiter; MRI = magnetic resonance imaging; PEI = percutaneous ethanol injection; PET = positron emission tomography; Tg = thyroglobulin; TIRADS = Thyroid Imaging Reporting and Data System; TPOAb = antithyroid peroxidase antibody; TSH = thyrotropin (thyroid-stimulating hormone); US = ultrasonography, ultrasonographic.
classification of FNA samples, (3) the roles of immunocytochemistry and molecular testing applied to thyroid FNA, (4) therapeutic options, and (5) follow-up strategy. Thyroid nodule management during pregnancy and in children are also addressed. On the basis of US features, thyroid nodules may be categorized into 3 groups: low-, intermediateand high-malignancy risk. FNA should be considered for nodules ≤10 mm diameter only when suspicious US signs are present, while nodules ≤5 mm should be monitored rather than biopsied. A classification scheme of 5 categories (nondiagnostic, benign, indeterminate, suspicious for malignancy, or malignant) is recommended for the cytologic report. Indeterminate lesions are further subdivided into 2 subclasses to more accurately stratify the risk of malignancy. At present, no single cytochemical or genetic marker can definitely rule out malignancy in indeterminate nodules. Nevertheless, these tools should be considered together with clinical data, US signs, elastographic pattern, or results of other imaging techniques to improve the management of these lesions. Most thyroid nodules do not require any treatment, and levothyroxine (LT 4 ) suppressive therapy is not recommended. Percutaneous ethanol injection (PEI) should be the first-line treatment option for relapsing, benign cystic lesions, while US-guided thermal ablation treatments may be considered for solid or mixed symptomatic benign thyroid nodules. Surgery remains the treatment of choice for malignant or suspicious nodules. The present document updates previous guidelines released in 2006 
I. INTRODUCTION
This document was prepared as a collaborative effort between the American Association of Clinical Endocrinologists (AACE), American College of Endocrinology (ACE) and Associazione Medici Endocrinologi (AME), Associazione Medici Endocrinologi). These guidelines cover diagnostic and therapeutic aspects of thyroid nodular disease but not thyroid cancer management. Suggestions for thyroid nodule management during pregnancy and childhood are also presented herein. The AACE protocol for standardized production of clinical practice guidelines was followed to rate the evidence level of each reference and to link the guidelines to the strength of recommendations (see Methods).
The basis of thyroid nodule management is the use of high-resolution ultrasonography (US), sensitive thyrotropin (TSH, formerly thyroid-stimulating hormone) assay, and fine-needle aspiration (FNA) biopsy, together with clinical findings. Thyroid scintigraphy is not necessary for diagnosis in most cases; however, it may be warranted in patients with a low serum TSH value or a multinodular gland to detect functional autonomy, most common in iodine-deficient areas. Measurement of serum TSH is the best initial laboratory test of thyroid function and should be followed by measurement of free thyroxine (FT 4 ) and free triiodothyronine (FT 3 ) when the TSH value is decreased, and measurement of thyroid peroxidase antibodies (TPOAbs) and FT 4 when the TSH value is above the reference range. A single, nonstimulated serum calcitonin measurement should be performed only when medullary thyroid carcinoma (MTC) is suspected due to FNA results or history.
Thyroid nodules are a common finding because they are detected in up to 50 to 60% of healthy people. In most cases, they appear in euthyroid persons and cause neither compressive symptoms nor cosmetic concerns. Accordingly, the main clinical challenge in the treatment of these patients is to rule out malignancy. Most patients with thyroid nodules are asymptomatic, but the absence of symptoms does not rule out malignancy. Thus, clinical and US risk factors for malignant disease should always be reviewed. All patients with a palpable thyroid nodule or clinical risk factors should undergo US examination.
Thyroid FNA should always be performed under US guidance because it makes the procedure safer, more reliable, and more accurate. In light of the low clinical risk, nodules <5 mm should always be monitored with US rather than biopsied. FNA should be considered for nodules with a major diameter ≤5-10 mm only when suspicious US signs are present (high US risk thyroid lesions) in association with pathologic lymph nodes or extrathyroidal spread. FNA is also appropriate in cases where the patient has a personal or family history of thyroid cancer or of coexistent suspicious clinical or imaging findings. FNA should be performed on nodules >10 mm that are devoid of suspicious US and/or clinical findings yet do not show a definite benign appearance (intermediate US risk thyroid lesions). Finally, FNA should be performed on spongiform, isohyperechoic, or predominantly (>50%) cystic nodules in the absence of suspicious US findings (low US risk thyroid lesions) only when nodules are ≥20 mm or progressively increasing in size. Nodules that are functioning on scintigraphy and devoid of suspicious US features can be excluded from FNA.
A classification scheme of 5 cytologic diagnostic categories and 2 subcategories is recommended for the cytologic report: nondiagnostic, benign, indeterminate, suspicious for malignancy, or malignant. Indeterminate lesions are further subdivided into 2 subclasses with significantly different estimated risks of cancer, to better stratify the risk of malignancy associated with the "indeterminate" nodules.
Nondiagnostic aspirates composed of pure colloid and obtained from a nodule that is completely cystic on US should be labeled as compatible with a colloid cyst and require clinical and US follow-up. Solid, persistently nondiagnostic nodules may be considered for US-guided core-needle biopsy (CNB) for microhistologic assessment. Alternatively, those with clearly favorable clinical and US findings can be monitored with close surveillance, whereas suspicious lesions should be surgically resected.
Nodules with benign cytologic characteristics should undergo clinical and US follow-up. A repeat FNA should be performed in the case of suspicious clinical and/or US findings or with substantial and progressive nodule enlargement, defined as a volume increase >50% (greater than the interobserver coefficient of variation). Most patients with benign thyroid nodules do not require any treatment; levothyroxine (LT 4 ) suppressive therapy is not recommended in euthyroid patients. In iodine-deficient geographic regions, iodine supplementation is recommended, and a trial of non-TSH-suppressive treatment with LT 4 may be considered in young patients with a small nodular goiter. Symptomatic goiters, whether euthyroid or hyperthyroid, may be treated surgically or with radioiodine. Percutaneous ethanol injection (PEI) is the first-line treatment of relapsing benign cystic thyroid lesions. In patients with solid or complex, symptomatic or progressively enlarging benign thyroid nodules, US-guided thermal ablation treatments may effectively control nodule growth and local symptoms.
Malignant or suspicious nodules should be treated surgically. Preoperative evaluation with US, FNA, and, if needed, further imaging techniques, is recommended for appropriate surgical planning.
In nodules with indeterminate cytologic results, no single cytochemical or genetic marker is specific or sensitive enough to rule out malignancy with certainty. However, the use of immunohistochemical and molecular markers may be considered together with the cytologic subcategories and data from US, elastography, or other imaging techniques to obtain additional information for management of these patients.
In selected cases (e.g., neck masses suspicious for lymph node metastasis from thyroid cancer, enlarged parathyroid glands), hormone measurement in the needle washouts increases FNA diagnostic accuracy.
These guidelines provide information to improve the management of patients with thyroid nodules. These recommendations must always take into account available local expertise, the clinical setting, and patient preference.
II. METHODS

Development and Use of the Guidelines:
Methods of Bibliographic Research We searched for primary evidence to support the current guidelines by using a "clinical question" method. Each topic covered by the guidelines was translated to a related question. Accordingly, the bibliographic research was conducted by selecting studies able to yield a methodologically reliable answer to each question. The first step was to select pertinent published reports. The U.S. National Library of Medicine Medical Subject Headings (MeSH) database was used as a terminologic filter. Appropriate MeSH terms were identified, and care was taken to select them on a sensitive rather than a specific basis. The MeSH terms and their proper combination enabled us to retrieve the reports pertinent to a specific issue.
The After the relevant published studies had been retrieved, the bibliographic research continued by looking for further evidence cited in the bibliography of each report and by following the Related Articles link listed next to each item in MEDLINE. Meta-analyses were searched both in MEDLINE and the Cochrane Library. Three methods were used to search for meta-analyses in MEDLINE:
• Selection of "Meta-Analysis" from the "Publication Type" menu on the "Limits" tab of the PubMed main page.
• Application of function "Find Systematic Reviews" on the "Clinical Queries" PubMed page. [tw] ). The Cochrane Library was browsed by entering free terms in the search window. Guidelines were searched in MEDLINE and several guidelines databases. Two methods were used to search for guidelines in MEDLINE:
• Selection of "Practice Guidelines" from the "Publication Type" menu on the "Limits" tab of the PubMed main page. 
Levels of Evidence and Grading of Recommendations
The AACE protocol for standardized production of clinical practice guidelines was followed to rate the evidence level of each reference on a scale of 1 to 4 and to link the guidelines to the strength of recommendations on the basis of grade designations A (action based on strong evidence) through D (action not based on any evidence or not recommended) ( Table 1 ) ). The BEL, corresponding to the best conclusive evidence found, accompanies the recommendation grade (5 [EL 4] ). All recommendations resulted from a consensus among the AACE and AME primary writers and were influenced by input from the Task Force members and reviewers.
Some recommendations were upgraded or downgraded on the basis of expert opinion. In these cases, subjective factors such as clinical experience, cost, risk, and regional availability of specific technologies and expertise took priority over the reported BEL.
III. EXECUTIVE SUMMARY
A. SECTIONS
To guide readers, the 2016 Clinical Practice Guidelines for the Diagnosis and Management of Thyroid Nodules are divided into the following sections:
• Readers are referred to the Appendix for more detail and supporting evidence for each section. • Focus the US report on stratification for risk of malignancy • Describe position, size, shape, margins, content, echogenic pattern, and vascular features of the nodule(s) • For multiple nodules, detail the nodule(s) bearing the US characteristics associated with malignancy rather than describing the largest (dominant) nodule. Table 4 ) [BEL 3, GRADE B].
US Classification Systems
The following US rating system of the risk of malignancy is suggested (see Table 5 and Fig. 1 and 2 Table  2 ) [BEL 2, GRADE A].
• Use the following reporting system for thyroid cytologic characteristics: Thyroid 1. Nondiagnostic.
• Inadequate or insufficient to make a diagnosis • Cystic: insufficient but consistent with a benign cystic lesion Thyroid 2. Benign. Thyroid 3. Indeterminate.
• Atypia or follicular lesion of undetermined significance (or a similar subclass in comparable cytologic classification systems [see Table 2 Fig. 1-3 
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